Akebia’s Vafseo gains FDA approval for anaemia due to CKD

2024-03-28
Pharmaceutical Technology
上市批准
Akebia’s Vafseo gains FDA approval for anaemia due to CKD
Preview
来源: Pharmaceutical Technology
Akebia plans to establish Vafseo as the new oral standard of care for adult patients undergoing dialysis. Credit: Tyler Olson / Shutterstock.com.
The US Food and Drug Administration (FDA) has approved Akebia Therapeutics‘ Vafseo (vadadustat) tablets for anaemia caused by chronic kidney disease (CKD) in adults on dialysis for a minimum of three months.
The once-daily oral medication is a hypoxia-inducible factor prolyl hydroxylase inhibitorhypoxia-inducible factor prolyl hydroxylase inhibitor, designed to trigger the body’s natural response to low oxygen levels and stimulate the production of erythropoietin.
Vafseo’s approval in the US follows its positive reception in 37 countries worldwide.
The FDA decision was based on safety and efficacy data from the INNO₂VATE programme and post-marketing safety data from Japan, where Vafseo has been available since August 2020.
Akebia is set to market Vafseo in the US with its experienced renal commercial team.
See Also:
Otsuka and Lundbeck’s schizophrenia treatment gains EC approval
Akebia’s Vafseo gains FDA approval for anaemia due to CKD
Preview
来源: Pharmaceutical Technology
Japan approves AstraZeneca’s Truqap with Faslodex for breast cancer
Akebia’s Vafseo gains FDA approval for anaemia due to CKD
Preview
来源: Pharmaceutical Technology
The company will capitalise on its partnership with speciality pharmaceuticals company CSL Vifor, which introduces innovative therapies to dialysis organisations in the US.
Akebia’s strategy is to establish Vafseo as the new oral standard of care for adult patients undergoing dialysis.
Akebia CEO John Butler stated: “With the approval of Vafseo in the US, we’re proud to deliver an alternative treatment option for the hundreds of thousands of Americans on dialysis who are diagnosed with anaemia due to CKD.
“At Akebia, we are committed to kidney patients, a dedication that has driven our team to achieve this milestone. We believe this commitment uniquely positions the company to execute a successful launch designed to drive toward a potential new oral standard of care for dialysis patients.”
In September 2023, the company received approval from Australia’s Therapeutic Goods Administration for Vafseo for the same indication.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。